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independent data. CONCLUSIONS: We found several well-designed models for dif-
ferent CML treatment strategies. However, the quality of reporting varied substan-
tially. We recommend that future models should include novel treatment options, 
subgroup evaluations for a more personalized decision making, and validation using 
independent data. Already available models with a short time horizon could be 
updated with new survival data.
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BACKGROUND: Extrapolation is often a key element in health economic modeling. 
Although any model should use empirical data if possible, the effects of treatments 
on long-term health outcomes are seldom observed within the follow-up time of a 
clinical study. Extrapolation over a lifetime horizon will generally be required in 
economic models where treatments have different cumulative survival at the end of 
the clinical trial. Typically, a within-trial analysis of costs and health effects, in which 
outcomes are truncated at the conclusion of the trial, will be overly conservative. 
OBJECTIVES: The purpose of this study is to compare different methods of extrapola-
tion in the context of examples concerning oncology, although the principles apply 
across all therapeutic areas. METHODS: There is a set of standard assumptions 
regarding extrapolation of survival data from clinical studies, ranging from very cau-
tious (“stop-and drop”) to very optimistic (“continued beneﬁ t”). The impact of dif-
ferent assumptions regarding extrapolation is explored, and the implications are 
discussed. CONCLUSIONS: The choice of extrapolation method has signiﬁ cant 
impact on comparative clinical effects, costs, and cost-effectiveness. Based on our 
ﬁ ndings and supporting examples, we propose the following: 1) Analysts should 
perform and report results under a range of speciﬁ c standard extrapolation assump-
tions to increase comparability across studies. 2) The choice of a base-case approach 
in any particular study should be guided by knowledge about the biology of the indica-
tion under evaluation and the mechanism of action of the treatment. A case could be 
made for a reference case method of extrapolation, but we believe that sensitivity 
analysis across a standard set of possibilities is sufﬁ cient. Adherence to these modeling 
practices will contribute to increased transparency in modeling and hence potentially 
to a greater conﬁ dence among health-care decision-makers in the results from cost-
effectiveness analyses building on modeling and extrapolation.
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OBJECTIVES: Challenges in analyzing cost data include addressing skewness in cost 
distributions, observed and unobserved heterogeneity across samples, and even more 
challenging complexities due to censoring. We combined generalized random effect 
models with inverse probability weighted (IPW) estimation techniques to address those 
challenges in a single model. METHODS: Generalized ﬁ xed effect models have been 
used with weights that are calculated as inverse due to probability being uncensored. 
The Gaussian family and log link function was chosen and we applied a test to see if 
possibly censoring bias exists. We also calculated the deviation from the consistent 
value if standard pooled ordinary least squares were used. RESULTS: A total of 4824 
observations were used in the analysis. We obtained Medicare claim ﬁ les for the 2 
years following patients’ lung cancer diagnosis. Costs had high kurtosis and skewness. 
Moreover, 30% of the cases were censored, and therefore, their annual costs were not 
observed. The total cost of all care was $63,000 for the 2 years following a lung cancer 
diagnosis and $57,000 for incomplete cases. Results signiﬁ cantly diverged from the 
standard regression model (P = 0.000). CONCLUSIONS: This paper applied inverse 
probability weighted estimation and ﬁ xed effect panel data models to an inception 
cohort of patients newly diagnosed with lung cancer. Our ﬁ ndings suggest that stan-
dard regression models yield inconsistent estimators due to censoring bias. The IPW 
least square estimation method removes that bias.
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OBJECTIVES: Chronic myelogenous leukemia (CML) is a progressive disease which 
arises from damage to the DNA of a stem cell in the bone marrow. This results in the 
uncontrolled growth of white blood cells which, in turn, can lead to severe impairment 
of an individual’s functioning. The National Institute for Health and Clinical Excel-
lence (NICE) models the costs and beneﬁ ts of medicines. The structure of these models 
is not prespeciﬁ ed and wide variations are often observed, both in the model’s choice 
of input parameters and in the structure of the modeling approach. While there is no 
such thing as a “correct” model, it is important that different models are compared 
and critiqued in order to identify any particular strengths and weaknesses of differing 
approaches. METHODS: A review was undertaken, identifying existing published 
models for CML. The data sources and choice of inputs were compared across each 
model and presented in a comparative table. Furthermore, the different approaches 
to model structure were examined, and attempts were made to explore the conse-
quences of each approach on the models, costs, effectiveness, and cost-effectiveness 
ﬁ ndings. RESULTS: The approaches to modeling CML vary signiﬁ cantly between 
different studies. While different data sources are utilitized in each model, this can 
usually be explained by emerging data which were not available to other researchers. 
However, the overall approach to modeling the disease varied considerably across 
each study. Model structures and assumptions for long-term outcomes were key 
drivers of the cost-effectiveness results in each model, but were often based on con-
trasting and contradicting approaches. CONCLUSIONS: This review has highlighted 
signiﬁ cant variation in approaches to modelling CML. It is recommended that long-
term follow-up from previously published trials should be used to predict the likely 
outcomes associated with shorter-term outcomes, such as treatment response.
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OBJECTIVES: Cost-effectiveness of chronic diseases drug-therapy is estimated with 
the help of various pharmacoeconomic analysis methods. Cost-effectiveness analysis, 
cost minimization analysis, cost-utility analysis, and cost-effectiveness analysis are 
used most often. We have proposed a modiﬁ cation of the cost-effectiveness analysis, 
which makes possible to record patient’s losses during treatment. Inﬂ ation coefﬁ cient 
K and its average value—Kmed may be more reliable tool in assessing the cost-
effectiveness of treatment of recurrent disease. METHODS: Formula evaluation of the 
effectiveness can be expressed as Kt &die;T DC(M/Nt), where k—coefﬁ cient of effec-
tiveness of treatment at time t DC—amount invested in the treatment of one person 
M—number of patients in the beginning of treatment (original group) N—number of 
patients at the time T t—regular interval, running on the account (month, day, year, 
etc.) RESULTS: Analysis of the coefﬁ cient K shows a tendency to increase with an 
increase in DC price for the treatment or—on decreasing the number of patients N, 
remaining in the group. As the period t becomes longer, entire formula is decreasing 
(inﬂ ation). The average coefﬁ cient k meaning is calculated according the formula 
Kmed &die;T ∑ Kt/t. Coefﬁ cient shows the average cost of one free of recurrence 
month in one patient from the group. The number of patients in group N decreases 
as a disease recurs, which leads to Kmed increase because of reallocating funds spent 
on chronic patients for the rest of patients. CONCLUSIONS: The study of economic 
efﬁ ciency through inﬂ ationary coefﬁ cient K, we have proposed, is a sensitive method 
for estimating treatment costs, and may prove to be a reliable tool for cost-effectiveness 
analysis of chronic patient drug therapy.
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OBJECTIVES: Studies evaluating computer-aided routinely assessment of patient-
reported outcomes (PRO) suggest important beneﬁ ts for physicians, patients, and their 
treatment. This project’s aim was developing a ﬂ ag system for computerized detection 
of cancer patients with additional treatment needs. METHODS: The detection system 
is part of the “Computer based Health Evaluation System (CHES),” a software for 
the computerized collection, processing, and presentation of PRO data. The ﬂ ag 
system helps identify cancer patients with conspicuous subscale patterns. This includes 
cutoff values (patients marked with orange or red buttons) and signiﬁ cant changes 
over time (yellow deltas). The testing data set was derived from a longitudinal study 
on QOL (assessed using the EORTC QLQ-C30) in chemotherapy patients at an 
oncological outpatient unit. Several criteria of “relevant” changes were compared 
regarding the prevalence of such changes in the study population and their statistical 
signiﬁ cance on an individual patient level. RESULTS: QOL data of 167 cancer patients 
were analyzed (on average 5.3 assessments per patient). The 75th and 90th percentile 
showed to be useful cutoff values. Recommended thresholds of relevant QOL changes 
appear to be unduly low when considering changes in the individual patient. Based 
on empirical data, we suggest a modiﬁ ed criterion of relevant change for the EORTC 
QLQ-C30 which appears clinically and statistically more meaningful. CONCLU-
SIONS: The developed ﬂ ag system enables physicians to detect patient-reported health 
deﬁ cits (e.g., fatigue) at one glance. However, more research involving various diag-
nostic groups is needed for a more profound empirical basis for developing reﬁ ned 
criteria.
